CLINICAL_TRIALS ClinicalTrials.gov record update

Korean Post-marketing Surveillance for Xeljanz® 5 mg Film-coated Tablets and Xeljanz® 1 mg/mL Oral Solution in Patients With Active pJIA and jPsA

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05754710
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:13.546312+00:00
Published At: 2026-03-13T00:00:00+00:00
Record Updated At: 2026-03-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Psoriatic Arthritis, Juvenile", "Polyarticular Juvenile Idiopathic Arthritis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-13"
protocolSection.identificationModule.nctId: "NCT05754710"
protocolSection.identificationModule.officialTitle: "Korean Post-marketing Surveillance for Xeljanz\u00ae 5 mg Film-coated Tablets and Xeljanz\u00ae 1 mg/mL Oral Solution in Patients With Active pJIA and jPsA"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.